Ginkgo Bioworks Holdings, Inc.
DNA
$6.79
-$0.45-6.22%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 3.50% | -41.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.50% | -41.69% | |||
| Cost of Revenue | -44.51% | -57.57% | |||
| Gross Profit | 12.59% | -37.24% | |||
| SG&A Expenses | -21.57% | -17.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.58% | -12.17% | |||
| Operating Income | 19.52% | -1.90% | |||
| Income Before Tax | 24.88% | 6.46% | |||
| Income Tax Expenses | 260.00% | 87.56% | |||
| Earnings from Continuing Operations | 24.64% | 5.81% | |||
| Earnings from Discontinued Operations | 262.55% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.44% | -2.27% | |||
| EBIT | 19.52% | -1.90% | |||
| EBITDA | 34.80% | -2.77% | |||
| EPS Basic | 45.75% | 1.99% | |||
| Normalized Basic EPS | 18.29% | -5.35% | |||
| EPS Diluted | 45.75% | 2.31% | |||
| Normalized Diluted EPS | 18.29% | -5.35% | |||
| Average Basic Shares Outstanding | 4.25% | 4.35% | |||
| Average Diluted Shares Outstanding | 4.25% | 4.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||